Authors

Newly Approved Specialty Drugs Advance Care for Inflammatory and Autoimmune Diseases

The Pharmacist’s Role in MS Supplement Safety

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Julie Kidd, PhD, MPH, BCPS, the director of clinical services at Blue Ridge Neurology, presenting on Supplements in Multiple Sclerosis, discussed what the pharmacist's role in MS supplement safety.

Optimizing Infusion Chair Time for Oncology Trials: Follow-Up Study

This study evaluated factors affecting the duration of the infusion appointment times for 392 clinical trial patients.

GLP-1s and Oncology: The Drug Interaction Clinicians Aren't Talking About

Patients with cancer on semaglutide or tirzepatide face hidden drug-drug interactions such as slowed absorption and nausea, requiring antiemetics and pharmacist coordination.

From Assessment to Discharge: Pharmacists Drive Safer, Patient-Centered Acute Pain Management

In an interview with Pharmacy Times, Brandon Kasberg, PharmD, discusses how pharmacists can help individualize multimodal acute pain regimens, reduce unnecessary opioid exposure, and support safer transitions from inpatient or postoperative care to the outpatient setting.

Afamitresgene autoleucel: The First T-Cell Receptor Therapy on the Market

Second-line and later treatment options for synovial sarcoma are limited. Afamitresgene autoleucel is the first FDA-approved T-cell receptor therapy, demonstrating long-lasting responses and tolerable adverse effects in pretreated patients.

Updated European MASLD Guidelines Review Prevention, Screening, and Treatments

Patients should be supported by a multidisciplinary team, frequent evaluations, and behavioral therapy for optimal care.

Deficiency in Care: Underutilization of Intravenous Iron for Acute Heart Failure

Ferric carboxymaltose is effective and guideline-endorsed, yet underutilized due to high cost and system-level barriers.

Levorphanol Safety and Clinical Practice: Risk Reduction, Workflow Impact, and the Pharmacist’s Role in Opioid Rotation

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and explores the safety profile of Levorphanol compared with methadone, including potential reductions in risks such as accumulation, QT prolongation, and drug interactions, as well as its implications for clinical workflows and the pharmacist’s role in supporting safe opioid rotation, monitoring, and patient counseling.

Meet the FDA’s Newly Approved OTC Sunscreen Ingredient: Bemotrizinol

In modernizing sunscreen options, the FDA has added the first new organic active ingredient, bemotrizinol, to the OTC sunscreen monograph.

What the Removal of Black Box Warnings Means for Women, Hormone Therapies, and Pharmacists

Pharmacists guide women through updated menopause hormone therapy labels, rising demand, patch shortages, and personalized risk-benefit counseling.

FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol

The 20-mg once-daily tablet is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C).

Standardizing Supplement Recommendations in a Neuro-Oncology Clinic: A Pharmacist-Led Quality Improvement Initiative

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Emerging Biomarkers and Precision Treatment Sequencing in Breast Cancer Care

The growing role of biomarker-driven treatment selection in breast cancer and how pharmacists can help optimize therapy sequencing, toxicity management, and personalized care.

DPYD Testing Gains Ground: NCCN Guideline Update Reflects Decades of Work Toward Safer Chemotherapy

Navigating Pediatric Atopic Dermatitis: Insights Into Treatment, Challenges, and Care Considerations

Atopic dermatitis significantly impacts quality of life, and requires personalized management through trigger identification, skin barrier maintenance, and a range of topical, oral, and biologic therapies to reduce symptoms and prevent flare-ups.

FGFR Inhibitors for Treatment of Primary CNS Tumors

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

HOPA 2025: Insights Into Post-Transplant Cyclophosphamide Use for Graft-Versus-Host Disease Prevention

Lauren Dietz, PharmD, highlighted the role of oncology pharmacists in guiding prophylaxis decisions to optimize transplant outcomes.

Essential Oils: A Pharmacist Guide for Alternative Pain Management

With Growing Patient Interest in Natural Remedies, Pharmacists Must Understand the Science, Safety, and Limitations of Essential Oils

What Hemophilia and Sickle Cell Disease Reveal About the Future of Gene Therapy Access

Alex Wolff, PharmD, BCOP, FHOPA, explains how patient populations, delivery models, and safety risks shape real-world implementation.

Improving Inpatient REMS Documentation Compliance With a Wildcard Checkpoint

Using wildcard hard-stop pharmacy preparation instructions in the electronic health record system significantly improved REMs documentation compliance at our institution.

Neuriva: A Closer Look at the Efficacy and Safety of this Popular Supplement

Administration of Tivozanib via Gastrostomy Tube: A Pharmacokinetic Analysis

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Hypertension: A Silent Killer Requiring Novel Therapies

Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action.

Half of Pharmacy Technicians Feel Fulfilled in Their Current Role

The Connecticut Society of Health-System Pharmacists Technician Committee survey explores the perception of career growth opportunities and challenges.

Strengthening Pharmacy Supply Chains: Strategies to Enhance Safety, Reliability, and Resilience

Why smarter supply chain management protects patients and pharmacy operations

Five Steps to Ensure Accurate 340B Program Data

Hospitals and health systems proactively monitor and manage data accuracy with third-party administrators to maintain 340B program compliance and maximize benefits for vulnerable patient populations.

Why Drug Information Infrastructure—Not Model Size—Will Define the Future of Health Care AI

As agentic AI enters clinical workflows, the real risk isn't processing power—it's whether AI systems can consistently access authoritative, real-time medication intelligence.

Cetirizine and Levocetirizine Withdrawal Pruritus: What Pharmacists Need to Know About the FDA’s New Safety Warning

The FDA issued a drug safety communication regarding rare but severe pruritus associated with discontinuation of long-term use of cetirizine or levocetirizine.

Preparing for the Medicare Transaction Facilitator